share_log

Chimerix | 8-K: Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update

Chimerix | 8-K: Chimerix Reports Third Quarter 2024 Financial Results and Provides Operational Update

Chimerix | 8-K:Chimerix公佈2024年第三季度財務業績並提供最新運營情況
美股SEC公告 ·  2024/11/07 12:13

牛牛AI助理已提取核心訊息

Chimerix reported a Q3 2024 net loss of $22.9M ($0.26 per share), compared to $24.0M loss in Q3 2023. Research and development expenses increased to $19.6M from $17.4M, while general and administrative expenses decreased to $5.2M from $9.3M. The company maintained a strong balance sheet with $152.4M in available capital as of September 30, 2024.The Phase 3 ACTION study for dordaviprone in H3 K27M-mutant diffuse glioma continues to progress, with first interim overall survival data expected in Q3 2025. The Independent Data Monitoring Committee recommended continuing the study as planned following a safety review. Additionally, Chimerix received alignment from Australia's TGA for Provisional Approval submission, with potential commercial availability by year-end 2025.The company promoted Dr. Josh Allen to Chief Scientific Officer and continues dose escalation studies of ONC206, with enrollment completion expected in 2024. ONC206 has shown no dose-limiting toxicity across 80+ patients, with objective response assessment planned for H1 2025.
Chimerix reported a Q3 2024 net loss of $22.9M ($0.26 per share), compared to $24.0M loss in Q3 2023. Research and development expenses increased to $19.6M from $17.4M, while general and administrative expenses decreased to $5.2M from $9.3M. The company maintained a strong balance sheet with $152.4M in available capital as of September 30, 2024.The Phase 3 ACTION study for dordaviprone in H3 K27M-mutant diffuse glioma continues to progress, with first interim overall survival data expected in Q3 2025. The Independent Data Monitoring Committee recommended continuing the study as planned following a safety review. Additionally, Chimerix received alignment from Australia's TGA for Provisional Approval submission, with potential commercial availability by year-end 2025.The company promoted Dr. Josh Allen to Chief Scientific Officer and continues dose escalation studies of ONC206, with enrollment completion expected in 2024. ONC206 has shown no dose-limiting toxicity across 80+ patients, with objective response assessment planned for H1 2025.
Chimerix報告2024年第三季度淨虧損2290萬(每股$0.26),相比之下2023年第三季度虧損2400萬。研發費用從1740萬增加到1960萬,而一般和行政費用則從930萬減少到520萬。截止到2024年9月30日,公司保持了強大的資產負債表,擁有15240萬的可用資本。針對dordaviprone的三期ACTION研究在H3 K2700萬突變擴散性神經膠質瘤中持續推進,預計在2025年第三季度將公佈首箇中期總體生存數據。獨立數據監控委員會在安全性審查後建議按計劃繼續該研究。此外,Chimerix還獲得了澳洲TGA對臨時審批提交的認可,預計到2025年底可能實現商業可用性。公司提升Dr. Josh Allen爲首席科學官,並繼續進行ONC206的劑量遞增研究,預計將在2024年完成招募。ONC206在80多名患者中未表現出劑量限制性毒性,計劃在2025年上半年進行客觀反應評估。
Chimerix報告2024年第三季度淨虧損2290萬(每股$0.26),相比之下2023年第三季度虧損2400萬。研發費用從1740萬增加到1960萬,而一般和行政費用則從930萬減少到520萬。截止到2024年9月30日,公司保持了強大的資產負債表,擁有15240萬的可用資本。針對dordaviprone的三期ACTION研究在H3 K2700萬突變擴散性神經膠質瘤中持續推進,預計在2025年第三季度將公佈首箇中期總體生存數據。獨立數據監控委員會在安全性審查後建議按計劃繼續該研究。此外,Chimerix還獲得了澳洲TGA對臨時審批提交的認可,預計到2025年底可能實現商業可用性。公司提升Dr. Josh Allen爲首席科學官,並繼續進行ONC206的劑量遞增研究,預計將在2024年完成招募。ONC206在80多名患者中未表現出劑量限制性毒性,計劃在2025年上半年進行客觀反應評估。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 398

熱點推薦

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。